tiprankstipranks
Calidi Biotherapeutics Reveals Promising Virotherapy Data
Company Announcements

Calidi Biotherapeutics Reveals Promising Virotherapy Data

Pick the best stocks and maximize your portfolio:

Calidi Biotherapeutics ( (CLDI) ) has provided an update.

Calidi Biotherapeutics has unveiled promising data showcasing its innovative RTNova systemic virotherapy technology, designed to effectively target metastatic lung cancer and other oncology indications. By utilizing a novel strain of vaccinia virus, RTNova overcomes challenges like rapid immune clearance, offering robust potential in treating and possibly transforming tumor environments. This advancement signifies a potential breakthrough in antitumor therapies, with opportunities for collaborative ventures with pharmaceutical partners.

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCalidi files to sell 6.94M shares of common stock for holders
TheFlyCalidi presents data on RTNova systemic technology in metastatic lung cancer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App